Tag: R&D

Research and development (R&D or R+D), also known in Europe as research and technical (or technological) development (RTD), is a general term for activities in connection with corporate or governmental innovation. Research and development is situated at the front end of the innovation life cycle, which may end with commercialization.

Zymeworks and Celgene expand their cooperation

test tubes
Zymeworks, a clinical-stage biopharmaceutical company, announced that Celgenehas exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutic.

CGT Catapult officially launched its cell and gene therapy manufacturing centre

dna
Cell and Gene Therapy Catapult officially opened its unique cell and gene therapy manufacturing centre. Backed by investment from UK Government, the centre will support and develop the global cell and gene therapy industry.

BenevolentAI received financing to push forward AI enabled drug development

lab
The company will use the funds to significantly scale its drug development activities, broaden the disease areas on which it focuses, and extend its AI platform capabilities even further.

Scancell obtains novel antibodies and immunotherapy technology

immunotherapy
Scancell Holdings, the developer of novel immunotherapies for the treatment of cancer, entered into an agreement with the University of Nottingham to acquire a number of novel monoclonal antibodies to tumour-associated glycans.

SAMDI Tech started partnership with Enamine

chemistry
SAMDI Tech, Inc., the industry’s leading provider of label-free drug discovery solutions, has partnered with Enamine, the world’s largest supplier of drug-like screening compounds.

Telix Pharmaceutical sets up research partnership with INSERM and ARRONAX

radiopharmaceuticals
Telix Pharmaceuticals announced a research partnership with the French National Institute of Health and Medical Research and the “Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic”.

Eisai will develop a new treatment for tuberculosis aided by US scientists

eisai
Japanese pharmaceutical company Eisai entered into a joint research agreement with the Broad Institute, Mycobacteria Research Laboratories at Colorado State University and the University of Chicago.

Arbutus and Roivant create Genevant Sciences to focus on RNA-based therapeutics

science
Arbutus Biopharma Corporation and Roivant Sciences entered into an agreement to launch Genevant Sciences, a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics.

Czech and US scientists discovered a new method to combat cancer

microscope
A team of Czech and US scientists have discovered a new method to fight cancer by blocking the access of a key nutrient, in this case an amino acid called glutamine, to cancer cells.

Inovio started new partnership with CEPI

vaccine
Inovio Pharmaceuticals and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a partnership under which Inovio will develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome (MERS).

Symcel starts collaboration with Karolinska Institutet

microbiology plates
Symcel, developer of the revolutionary cell-based assay tool for real-time cell metabolism measurements, partnered with the Karolinska Institutet in a Horizon 2020 funded project.

Pfizer enters into the global health research network TriNetX

pfizer
As a member, Pfizer will have access to clinical data from TriNetX's network of healthcare organizations to support clinical study and protocol design, site identification, and patient recruitment for clinical trials.

Chinese biotech Biocytogen received $65 million investment

biotechnology
CMB International Capital Corporation, a wholly-owned subsidiary of China Merchants Bank, provided a $65 million budgeting for Beijing Biocytogen, a gene targeted animal model and service supplier.

Charles River Laboratories extends cooperation with PathoQuest

laboratory
Charles River Laboratories International and PathoQuest announced an expansion of their strategic partnership agreement to provide next-generation sequencing (NGS) services to the biologics industry.

Frontage Laboratories acquired Concord Biosciences

drug_development
Frontage Laboratories, Inc., a global contract research organisation (CRO), announced the acquisition of Concord Biosciences (Cleveland, USA) formerly known as Ricerca Biosciences, LLC, a preclinical CRO.

China stimulates the research and development of generics

generics
With support in research and development, registration of Chinese generic drugs and marketing of the drugs in the global market, companies will be encouraged by the government to carry out international cooperation.